Shortage of lofexidine hydrochloride tablets 200 microgram (Britoflex)

Lofexidine is licensed for the management of symptoms of opioid detoxification. Britannia Pharmaceuticals has advised that the current batch of product expires end of May 2018, and due to change in manufacturer it is unlikely that the product will be available for several months. This memo provides advice on management of patients during the shortage.

LofexidineMental HealthMental health and illnessNewsShortages, Discontinuations and Patent Expiries

Attachments